{"transactions":[{"id":730564,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:14:12.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.28,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001543792-26-000002","document":"wk-form4_1782159249.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000154379226000002/wk-form4_1782159249.xml","form_type":"4"}},{"id":730563,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36353,"kind":"person","name":"NAZEM FARZAD","position":1,"cik":"0001234663","reported_name":"NAZEM FARZAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:14:06.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.28,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001234663-26-000002","document":"wk-form4_1782159243.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000123466326000002/wk-form4_1782159243.xml","form_type":"4"}},{"id":730562,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36352,"kind":"person","name":"Akinsanya Karen","position":1,"cik":"0001797672","reported_name":"Akinsanya Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:13:59.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.28,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001797672-26-000004","document":"wk-form4_1782159237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000179767226000004/wk-form4_1782159237.xml","form_type":"4"}},{"id":730561,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36351,"kind":"person","name":"McIlwain Matthew S","position":1,"cik":"0001381752","reported_name":"McIlwain Matthew S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:13:53.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.28,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001381752-26-000001","document":"wk-form4_1782159231.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000138175226000001/wk-form4_1782159231.xml","form_type":"4"}},{"id":730559,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:13:47.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.28,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001807359-26-000008","document":"wk-form4_1782159224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180735926000008/wk-form4_1782159224.xml","form_type":"4"}},{"id":749956,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":28074,"kind":"organization","name":"AH Equity Partners Bio II, L.L.C.","position":1,"cik":"0001725722","reported_name":"AH Equity Partners Bio II, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41435,"kind":"organization","name":"Andreessen Horowitz LSV Fund II, L.P.","position":2,"cik":"0001829357","reported_name":"Andreessen Horowitz LSV Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":28073,"kind":"organization","name":"AH Bio Fund II, L.P.","position":3,"cik":"0001725721","reported_name":"AH Bio Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41436,"kind":"organization","name":"AH Equity Partners LSV II, L.L.C.","position":4,"cik":"0001829384","reported_name":"AH Equity Partners LSV II, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":10500,"kind":"person","name":"Andreessen Marc L","position":5,"cik":"0001160077","reported_name":"Andreessen Marc L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20480,"kind":"person","name":"HOROWITZ BENJAMIN A","position":6,"cik":"0001166586","reported_name":"HOROWITZ BENJAMIN A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-04T20:53:45.000Z","date":"2026-06-02","kind":"sale","planned":false,"acquired":false,"shares":384026,"price":2.35,"value":902461.1,"ownership":{"direct":false,"nature":"By Andreessen Horowitz LSV Fund II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Andreessen Horowitz LSV Fund II, L.P. (\"AH LSV Fund II\"), for itself and as nominee for Andreessen Horowitz LSV Fund II-B, L.P. and Andreessen Horowitz LSV Fund II-Q, L.P. AH Equity Partners LSV II, L.L.C. (\"AH EP LSV II\") is the general partner of AH LSV Fund II and has sole voting and dispositive power with regard to the securities held by AH LSV Fund II for itself and as nominee. The managing members of AH EP LSV II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH LSV Fund II for itself and as nominee."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of the securities held by AH LSV Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":971885,"source":{"system":"sec-edgar","filing":"0001231919-26-000599","document":"form4-06042026_080637.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1160077/000123191926000599/form4-06042026_080637.xml","form_type":"4"}},{"id":749955,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":28074,"kind":"organization","name":"AH Equity Partners Bio II, L.L.C.","position":1,"cik":"0001725722","reported_name":"AH Equity Partners Bio II, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41435,"kind":"organization","name":"Andreessen Horowitz LSV Fund II, L.P.","position":2,"cik":"0001829357","reported_name":"Andreessen Horowitz LSV Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":28073,"kind":"organization","name":"AH Bio Fund II, L.P.","position":3,"cik":"0001725721","reported_name":"AH Bio Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41436,"kind":"organization","name":"AH Equity Partners LSV II, L.L.C.","position":4,"cik":"0001829384","reported_name":"AH Equity Partners LSV II, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":10500,"kind":"person","name":"Andreessen Marc L","position":5,"cik":"0001160077","reported_name":"Andreessen Marc L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20480,"kind":"person","name":"HOROWITZ BENJAMIN A","position":6,"cik":"0001166586","reported_name":"HOROWITZ BENJAMIN A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-04T20:53:45.000Z","date":"2026-06-02","kind":"sale","planned":false,"acquired":false,"shares":4615974,"price":2.35,"value":10847538.9,"ownership":{"direct":false,"nature":"By AH Bio Fund II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by AH Bio Fund II, L.P. (\"AH Bio Fund II\"), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (\"AH EP Bio II\") is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Persons disclaims the existence of a \"group\" and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":11682032,"source":{"system":"sec-edgar","filing":"0001231919-26-000599","document":"form4-06042026_080637.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1160077/000123191926000599/form4-06042026_080637.xml","form_type":"4"}},{"id":861776,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Common Stock","published_at":"2026-03-04T23:37:20.000Z","date":"2026-03-04","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":2.6095,"value":65237.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $2.48 to $2.6095 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10366721,"source":{"system":"sec-edgar","filing":"0001378830-26-000003","document":"wk-form4_1772667437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000137883026000003/wk-form4_1772667437.xml","form_type":"4"}},{"id":861775,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62838,"kind":"person","name":"Mowry Anna","position":1,"cik":"0001856938","reported_name":"Mowry Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T22:31:36.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026."}],"balance_after":160000,"derivative":{"exercise_price":2.32,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001856938-26-000001","document":"wk-form4_1772663494.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000185693826000001/wk-form4_1772663494.xml","form_type":"4"}},{"id":861774,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62837,"kind":"person","name":"Mallick Parag","position":1,"cik":"0001857948","reported_name":"Mallick Parag","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T22:31:31.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026."}],"balance_after":280000,"derivative":{"exercise_price":2.32,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001857948-26-000001","document":"wk-form4_1772663489.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000185794826000001/wk-form4_1772663489.xml","form_type":"4"}},{"id":861773,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T22:31:27.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026."}],"balance_after":650000,"derivative":{"exercise_price":2.32,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001378830-26-000001","document":"wk-form4_1772663485.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000137883026000001/wk-form4_1772663485.xml","form_type":"4"}},{"id":861772,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62835,"kind":"person","name":"Sankar Subramanian","position":1,"cik":"0001856744","reported_name":"Sankar Subramanian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Product Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T22:31:22.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026."}],"balance_after":160000,"derivative":{"exercise_price":2.32,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001856744-26-000001","document":"wk-form4_1772663480.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000185674426000001/wk-form4_1772663480.xml","form_type":"4"}},{"id":861771,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62834,"kind":"person","name":"Weld Gwen E","position":1,"cik":"0001378831","reported_name":"Weld Gwen E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T22:31:17.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026."}],"balance_after":160000,"derivative":{"exercise_price":2.32,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001378831-26-000001","document":"wk-form4_1772663474.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000137883126000001/wk-form4_1772663474.xml","form_type":"4"}},{"id":861958,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62851,"kind":"person","name":"Murphy Matthew B.","position":1,"cik":"0001865778","reported_name":"Murphy Matthew B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T17:31:12.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026."}],"balance_after":160000,"derivative":{"exercise_price":2.32,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001865778-26-000001","document":"wk-form4_1772663469.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865778/000186577826000001/wk-form4_1772663469.xml","form_type":"4"}},{"id":862312,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62888,"kind":"person","name":"Suzuki Kentaro","position":1,"cik":"0002037191","reported_name":"Suzuki Kentaro","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Marketing Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T17:31:07.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026."}],"balance_after":160000,"derivative":{"exercise_price":2.32,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0002037191-26-000001","document":"wk-form4_1772663465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037191/000203719126000001/wk-form4_1772663465.xml","form_type":"4"}},{"id":1003926,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62888,"kind":"person","name":"Suzuki Kentaro","position":1,"cik":"0002037191","reported_name":"Suzuki Kentaro","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Marketing Officer"}}],"security":"Common Stock","published_at":"2025-11-10T21:29:14.000Z","date":"2025-11-06","kind":"purchase","planned":false,"acquired":true,"shares":4000,"price":1.49,"value":5960.0,"ownership":{"direct":true},"balance_after":4000,"source":{"system":"sec-edgar","filing":"0002037191-25-000004","document":"wk-form4_1762828151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037191/000203719125000004/wk-form4_1762828151.xml","form_type":"4"}},{"id":1044883,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Common Stock","published_at":"2025-09-09T20:42:25.000Z","date":"2025-09-08","kind":"purchase","planned":false,"acquired":true,"shares":83500,"price":0.683,"value":57030.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 83,500 shares purchased in the price range of $0.6581 to $0.7145 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10341721,"source":{"system":"sec-edgar","filing":"0001378830-25-000003","document":"wk-form4_1757450542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000137883025000003/wk-form4_1757450542.xml","form_type":"4"}},{"id":1044882,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Common Stock","published_at":"2025-09-09T20:42:25.000Z","date":"2025-09-05","kind":"purchase","planned":false,"acquired":true,"shares":116500,"price":0.6742,"value":78544.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 116,500 shares purchased in the price range of $0.6547 to $0.6899 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10258221,"source":{"system":"sec-edgar","filing":"0001378830-25-000003","document":"wk-form4_1757450542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000137883025000003/wk-form4_1757450542.xml","form_type":"4"}},{"id":1046894,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62851,"kind":"person","name":"Murphy Matthew B.","position":1,"cik":"0001865778","reported_name":"Murphy Matthew B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-09-05T18:34:20.000Z","date":"2025-09-04","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.6429,"value":12858.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by the Murphy Family Trust. The reporting person is the Trustee of the Murphy Family Trust."}],"balance_after":74140,"source":{"system":"sec-edgar","filing":"0001865778-25-000003","document":"wk-form4_1757111657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865778/000186577825000003/wk-form4_1757111657.xml","form_type":"4"}},{"id":1101745,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T20:37:40.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":0.6951,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-25-000064","document":"wk-form4_1750883852.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000064/wk-form4_1750883852.xml","form_type":"4"}},{"id":1101740,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T20:37:28.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":0.6951,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-25-000063","document":"wk-form4_1750883840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000063/wk-form4_1750883840.xml","form_type":"4"}},{"id":1101739,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36351,"kind":"person","name":"McIlwain Matthew S","position":1,"cik":"0001381752","reported_name":"McIlwain Matthew S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T20:37:16.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":0.6951,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-25-000062","document":"wk-form4_1750883829.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000062/wk-form4_1750883829.xml","form_type":"4"}},{"id":1101738,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36353,"kind":"person","name":"NAZEM FARZAD","position":1,"cik":"0001234663","reported_name":"NAZEM FARZAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T20:37:05.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":0.6951,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-25-000061","document":"wk-form4_1750883818.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000061/wk-form4_1750883818.xml","form_type":"4"}},{"id":1101737,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36352,"kind":"person","name":"Akinsanya Karen","position":1,"cik":"0001797672","reported_name":"Akinsanya Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T20:36:55.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":0.6951,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-25-000060","document":"wk-form4_1750883807.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000060/wk-form4_1750883807.xml","form_type":"4"}},{"id":1127774,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62838,"kind":"person","name":"Mowry Anna","position":1,"cik":"0001856938","reported_name":"Mowry Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2025-06-02T21:12:33.000Z","date":"2025-05-29","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.7659,"value":11488.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 15,000 shares purchased in the price range of $0.7662 to $0.7489 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the following shares of Common Stock acquired through the Issuer's 2021 Employee Stock Purchase Plan: (i) 1,250 shares on December 1, 2022; (ii) 1,250 shares on June 1, 2023; (iii) 1,250 shares on December 1, 2023; (iv) 2,500 shares on May 31, 2024; (v) 2,500 shares on November 29, 2024; and (vi) 2,500 shares on May 30, 2025."}],"balance_after":83000,"source":{"system":"sec-edgar","filing":"0001808805-25-000051","document":"wk-form4_1748898746.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000051/wk-form4_1748898746.xml","form_type":"4"}},{"id":1152282,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62837,"kind":"person","name":"Mallick Parag","position":1,"cik":"0001857948","reported_name":"Mallick Parag","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Common Stock","published_at":"2025-05-12T23:19:33.000Z","date":"2025-05-12","kind":"purchase","planned":false,"acquired":true,"shares":1500,"price":0.7317,"value":1097.55,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 1,500 shares purchased in the price range of $0.7229 to $0.7334 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":20493392,"source":{"system":"sec-edgar","filing":"0001808805-25-000049","document":"wk-form4_1747091966.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000049/wk-form4_1747091966.xml","form_type":"4"}},{"id":1152281,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62837,"kind":"person","name":"Mallick Parag","position":1,"cik":"0001857948","reported_name":"Mallick Parag","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Common Stock","published_at":"2025-05-12T23:19:33.000Z","date":"2025-05-08","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":0.7323,"value":8787.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 12,000 shares purchased in the price range of $0.7058 to $0.7520 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":20491892,"source":{"system":"sec-edgar","filing":"0001808805-25-000049","document":"wk-form4_1747091966.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000049/wk-form4_1747091966.xml","form_type":"4"}},{"id":1194701,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Common Stock","published_at":"2025-03-21T20:44:37.000Z","date":"2025-03-20","kind":"purchase","planned":false,"acquired":true,"shares":23933,"price":0.9982,"value":23889.9206,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 23,933 shares purchased in the price range of $0.9351 to $1.06 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10141721,"source":{"system":"sec-edgar","filing":"0001808805-25-000034","document":"wk-form4_1742589871.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000034/wk-form4_1742589871.xml","form_type":"4"}},{"id":1194700,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Common Stock","published_at":"2025-03-21T20:44:37.000Z","date":"2025-03-19","kind":"purchase","planned":false,"acquired":true,"shares":53300,"price":0.9949,"value":53028.17,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 53,300 shares purchased in the price range of $0.9469 to $1.10 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10117788,"source":{"system":"sec-edgar","filing":"0001808805-25-000034","document":"wk-form4_1742589871.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000034/wk-form4_1742589871.xml","form_type":"4"}},{"id":1229115,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62838,"kind":"person","name":"Mowry Anna","position":1,"cik":"0001856938","reported_name":"Mowry Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:52:41.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025."}],"balance_after":160000,"derivative":{"exercise_price":1.24,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-25-000025","document":"wk-form4_1741125151.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000025/wk-form4_1741125151.xml","form_type":"4"}},{"id":1229114,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":82464,"kind":"person","name":"Nelson Nicholas A.","position":1,"cik":"0001857944","reported_name":"Nelson Nicholas A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO & Senior VP, Bus. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:52:28.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025."}],"balance_after":160000,"derivative":{"exercise_price":1.24,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-25-000024","document":"wk-form4_1741125139.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000024/wk-form4_1741125139.xml","form_type":"4"}},{"id":1229112,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62834,"kind":"person","name":"Weld Gwen E","position":1,"cik":"0001378831","reported_name":"Weld Gwen E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:52:15.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025."}],"balance_after":160000,"derivative":{"exercise_price":1.24,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-25-000023","document":"wk-form4_1741125127.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000023/wk-form4_1741125127.xml","form_type":"4"}},{"id":1229111,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62837,"kind":"person","name":"Mallick Parag","position":1,"cik":"0001857948","reported_name":"Mallick Parag","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:51:51.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025."}],"balance_after":280000,"derivative":{"exercise_price":1.24,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001808805-25-000021","document":"wk-form4_1741125102.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000021/wk-form4_1741125102.xml","form_type":"4"}},{"id":1229113,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:51:39.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025."}],"balance_after":650000,"derivative":{"exercise_price":1.24,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001808805-25-000020","document":"wk-form4_1741125091.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000020/wk-form4_1741125091.xml","form_type":"4"}},{"id":1229110,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62835,"kind":"person","name":"Sankar Subramanian","position":1,"cik":"0001856744","reported_name":"Sankar Subramanian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Product Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:51:29.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025."}],"balance_after":160000,"derivative":{"exercise_price":1.24,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-25-000019","document":"wk-form4_1741125080.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000019/wk-form4_1741125080.xml","form_type":"4"}},{"id":1229419,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62851,"kind":"person","name":"Murphy Matthew B.","position":1,"cik":"0001865778","reported_name":"Murphy Matthew B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T16:52:51.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025."}],"balance_after":160000,"derivative":{"exercise_price":1.24,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-25-000026","document":"wk-form4_1741125162.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865778/000180880525000026/wk-form4_1741125162.xml","form_type":"4"}},{"id":1230139,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62888,"kind":"person","name":"Suzuki Kentaro","position":1,"cik":"0002037191","reported_name":"Suzuki Kentaro","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Marketing Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T16:52:04.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025."}],"balance_after":50000,"derivative":{"exercise_price":1.24,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001808805-25-000022","document":"wk-form4_1741125115.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037191/000180880525000022/wk-form4_1741125115.xml","form_type":"4"}},{"id":1399508,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":87261,"kind":"person","name":"Godwin Mary E.","position":1,"cik":"0001439716","reported_name":"Godwin Mary E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-25T22:29:21.000Z","date":"2024-09-23","kind":"exercise","planned":false,"acquired":false,"shares":47031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement date is January 21, 2020."}],"balance_after":353337,"derivative":{"exercise_price":0.46,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":47031},"source":{"system":"sec-edgar","filing":"0001808805-24-000067","document":"wk-form4_1727303354.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000067/wk-form4_1727303354.xml","form_type":"4"}},{"id":1399507,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":87261,"kind":"person","name":"Godwin Mary E.","position":1,"cik":"0001439716","reported_name":"Godwin Mary E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Operations"}}],"security":"Common Stock","published_at":"2024-09-25T22:29:21.000Z","date":"2024-09-23","kind":"sale","planned":false,"acquired":false,"shares":47031,"price":2.865,"value":134743.815,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 47,031 shares purchased in the price range of $2.80 to $3.02 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001808805-24-000067","document":"wk-form4_1727303354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000067/wk-form4_1727303354.xml","form_type":"4"}},{"id":1399506,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":87261,"kind":"person","name":"Godwin Mary E.","position":1,"cik":"0001439716","reported_name":"Godwin Mary E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Operations"}}],"security":"Common Stock","published_at":"2024-09-25T22:29:21.000Z","date":"2024-09-23","kind":"exercise","planned":false,"acquired":true,"shares":47031,"price":0.46,"value":21634.26,"ownership":{"direct":true},"balance_after":47031,"source":{"system":"sec-edgar","filing":"0001808805-24-000067","document":"wk-form4_1727303354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000067/wk-form4_1727303354.xml","form_type":"4"}},{"id":1403687,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":87261,"kind":"person","name":"Godwin Mary E.","position":1,"cik":"0001439716","reported_name":"Godwin Mary E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-18T22:32:06.000Z","date":"2024-09-17","kind":"exercise","planned":false,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement date is January 21, 2020."}],"balance_after":400368,"derivative":{"exercise_price":0.46,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001808805-24-000065","document":"wk-form4_1726698721.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000065/wk-form4_1726698721.xml","form_type":"4"}},{"id":1403686,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":87261,"kind":"person","name":"Godwin Mary E.","position":1,"cik":"0001439716","reported_name":"Godwin Mary E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Operations"}}],"security":"Common Stock","published_at":"2024-09-18T22:32:06.000Z","date":"2024-09-17","kind":"sale","planned":false,"acquired":false,"shares":35000,"price":2.8534,"value":99869.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 35,000 shares purchased in the price range of $2.80 to $2.99  by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001808805-24-000065","document":"wk-form4_1726698721.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000065/wk-form4_1726698721.xml","form_type":"4"}},{"id":1403685,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":87261,"kind":"person","name":"Godwin Mary E.","position":1,"cik":"0001439716","reported_name":"Godwin Mary E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Operations"}}],"security":"Common Stock","published_at":"2024-09-18T22:32:06.000Z","date":"2024-09-17","kind":"exercise","planned":false,"acquired":true,"shares":35000,"price":0.46,"value":16100.0,"ownership":{"direct":true},"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001808805-24-000065","document":"wk-form4_1726698721.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000065/wk-form4_1726698721.xml","form_type":"4"}},{"id":1405502,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62888,"kind":"person","name":"Suzuki Kentaro","position":1,"cik":"0002037191","reported_name":"Suzuki Kentaro","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Marketing Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-17T16:47:37.000Z","date":"2024-09-16","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the reporting person remains a Service Provider as provided in the Company's 2021 Equity Incentive Plan through each such vesting date. The Vesting Commencement Date is September 16, 2024."}],"balance_after":375000,"derivative":{"exercise_price":2.96,"expiration_date":"2034-09-16","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001808805-24-000063","document":"wk-form4_1726606041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037191/000180880524000063/wk-form4_1726606041.xml","form_type":"4"}},{"id":1477413,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36351,"kind":"person","name":"McIlwain Matthew S","position":1,"cik":"0001381752","reported_name":"McIlwain Matthew S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T22:09:14.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.56,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-24-000052","document":"wk-form4_1718662147.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000052/wk-form4_1718662147.xml","form_type":"4"}},{"id":1477412,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T22:03:29.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date."}],"balance_after":45000,"derivative":{"exercise_price":2.56,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001062993-24-012727","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000106299324012727/form4.xml","form_type":"4"}},{"id":1477645,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T22:02:16.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the continuous status of Mr. Altman as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of the grant on the same day of the month as such grant date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of options to purchase shares of the Issuer's common stock awarded to Michael Altman in connection with his role as a member of the Issuer's Board of Directors. Mr. Altman is affiliated with Perceptive Advisors LLC (the \"Advisor\"). The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Altman's board service through a partial management fee offset."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Joseph Edelman is the managing member of the Advisor. The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\"). Each of Mr. Edelman, the Master Fund and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of the securities reported on this form, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman, the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":45000,"derivative":{"exercise_price":2.56,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001062993-24-012726","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299324012726/form4.xml","form_type":"4"}},{"id":1477411,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36352,"kind":"person","name":"Akinsanya Karen","position":1,"cik":"0001797672","reported_name":"Akinsanya Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T21:40:30.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.56,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-24-000051","document":"wk-form4_1718660424.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000051/wk-form4_1718660424.xml","form_type":"4"}},{"id":1477410,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T21:37:24.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.56,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-24-000050","document":"wk-form4_1718660238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000050/wk-form4_1718660238.xml","form_type":"4"}},{"id":1477409,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T21:35:30.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.56,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-24-000049","document":"wk-form4_1718660123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000049/wk-form4_1718660123.xml","form_type":"4"}},{"id":1477408,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36353,"kind":"person","name":"NAZEM FARZAD","position":1,"cik":"0001234663","reported_name":"NAZEM FARZAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T21:24:38.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.56,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-24-000048","document":"wk-form4_1718659469.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000048/wk-form4_1718659469.xml","form_type":"4"}},{"id":1477407,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T21:03:52.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":2.56,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-24-000045","document":"wk-form4_1718658225.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000045/wk-form4_1718658225.xml","form_type":"4"}},{"id":1584345,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Common Stock","published_at":"2024-03-12T00:21:59.000Z","date":"2024-03-11","kind":"purchase","planned":false,"acquired":true,"shares":12044,"price":2.8409,"value":34215.7996,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 12,044 shares purchased in the price range of $2.75 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10064488,"source":{"system":"sec-edgar","filing":"0001808805-24-000026","document":"wk-form4_1710202909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000026/wk-form4_1710202909.xml","form_type":"4"}},{"id":1584344,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Common Stock","published_at":"2024-03-12T00:21:59.000Z","date":"2024-03-08","kind":"purchase","planned":false,"acquired":true,"shares":2430,"price":2.9885,"value":7262.055,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 2,430  shares purchased in the price range of $2.96 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10052444,"source":{"system":"sec-edgar","filing":"0001808805-24-000026","document":"wk-form4_1710202909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000026/wk-form4_1710202909.xml","form_type":"4"}},{"id":1589290,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Common Stock","published_at":"2024-03-08T00:06:49.000Z","date":"2024-03-07","kind":"purchase","planned":false,"acquired":true,"shares":18854,"price":2.8866,"value":54423.9564,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 18,854  shares purchased in the price range of $2.72 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10050014,"source":{"system":"sec-edgar","filing":"0001628280-24-009754","document":"wk-form4_1709856399.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000162828024009754/wk-form4_1709856399.xml","form_type":"4"}},{"id":1589289,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Common Stock","published_at":"2024-03-08T00:06:49.000Z","date":"2024-03-06","kind":"purchase","planned":false,"acquired":true,"shares":9267,"price":2.7014,"value":25033.8738,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 9,267 shares purchased in the price range of $2.64 to $2.77 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10031160,"source":{"system":"sec-edgar","filing":"0001628280-24-009754","document":"wk-form4_1709856399.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000162828024009754/wk-form4_1709856399.xml","form_type":"4"}},{"id":1589288,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Common Stock","published_at":"2024-03-08T00:06:49.000Z","date":"2024-03-05","kind":"purchase","planned":false,"acquired":true,"shares":7405,"price":2.6464,"value":19596.592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 7,405 shares purchased in the price range of $2.58 to $2.69 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10021893,"source":{"system":"sec-edgar","filing":"0001628280-24-009754","document":"wk-form4_1709856399.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000162828024009754/wk-form4_1709856399.xml","form_type":"4"}},{"id":1596999,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-05T21:52:25.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024."}],"balance_after":650000,"derivative":{"exercise_price":2.72,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001808805-24-000024","document":"wk-form4_1709675514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000024/wk-form4_1709675514.xml","form_type":"4"}},{"id":1596998,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62837,"kind":"person","name":"Mallick Parag","position":1,"cik":"0001857948","reported_name":"Mallick Parag","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-05T21:49:20.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024."}],"balance_after":280000,"derivative":{"exercise_price":2.72,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001808805-24-000022","document":"wk-form4_1709675334.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000022/wk-form4_1709675334.xml","form_type":"4"}},{"id":1596997,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":82464,"kind":"person","name":"Nelson Nicholas A.","position":1,"cik":"0001857944","reported_name":"Nelson Nicholas A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO & Senior VP, Bus. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-05T21:46:12.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024."}],"balance_after":160000,"derivative":{"exercise_price":2.72,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-24-000020","document":"wk-form4_1709675142.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000020/wk-form4_1709675142.xml","form_type":"4"}},{"id":1596995,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62838,"kind":"person","name":"Mowry Anna","position":1,"cik":"0001856938","reported_name":"Mowry Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-05T21:42:01.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024."}],"balance_after":160000,"derivative":{"exercise_price":2.72,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-24-000018","document":"wk-form4_1709674895.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000018/wk-form4_1709674895.xml","form_type":"4"}},{"id":1596996,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62834,"kind":"person","name":"Weld Gwen E","position":1,"cik":"0001378831","reported_name":"Weld Gwen E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-05T21:37:29.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024."}],"balance_after":160000,"derivative":{"exercise_price":2.72,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-24-000016","document":"wk-form4_1709674619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000016/wk-form4_1709674619.xml","form_type":"4"}},{"id":1596994,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62835,"kind":"person","name":"Sankar Subramanian","position":1,"cik":"0001856744","reported_name":"Sankar Subramanian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Product Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-05T21:30:01.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024."}],"balance_after":160000,"derivative":{"exercise_price":2.72,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-24-000012","document":"wk-form4_1709674183.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000012/wk-form4_1709674183.xml","form_type":"4"}},{"id":1596993,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":87261,"kind":"person","name":"Godwin Mary E.","position":1,"cik":"0001439716","reported_name":"Godwin Mary E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-05T21:23:28.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024."}],"balance_after":160000,"derivative":{"exercise_price":2.72,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-24-000010","document":"wk-form4_1709673794.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880524000010/wk-form4_1709673794.xml","form_type":"4"}},{"id":1597406,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62851,"kind":"person","name":"Murphy Matthew B.","position":1,"cik":"0001865778","reported_name":"Murphy Matthew B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-05T16:34:18.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024."}],"balance_after":160000,"derivative":{"exercise_price":2.72,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-24-000014","document":"wk-form4_1709674435.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865778/000180880524000014/wk-form4_1709674435.xml","form_type":"4"}},{"id":1850110,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":2,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":3,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-21T01:07:00.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the continuous status of Mr. Altman as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each vesting date, the shares subject to the Option shall vest on a monthly basis for twelve consecutive months, on the same day of the month as the Grant Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of options to purchase shares of the Issuer's common stock awarded to Michael Altman in connection with his role as a member of the Issuer's Board of Directors.  Mr. Altman is affiliated with the Advisor.  The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Altman's board service through a partial management fee offset."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Joseph Edelman is the managing member of the Advisor.  The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\"). Each of Mr. Edelman, the Mater Fund and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of the securities reported on this form, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman, the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":45000,"derivative":{"exercise_price":3.97,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-23-016076","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000089924323016076/doc4.xml","form_type":"4"}},{"id":1849708,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-21T00:52:46.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date."}],"balance_after":45000,"derivative":{"exercise_price":3.97,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-23-016073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000089924323016073/doc4.xml","form_type":"4"}},{"id":1852487,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36351,"kind":"person","name":"McIlwain Matthew S","position":1,"cik":"0001381752","reported_name":"McIlwain Matthew S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-17T00:07:02.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":3.97,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-23-000064","document":"wf-form4_168696040915626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000064/wf-form4_168696040915626.xml","form_type":"4"}},{"id":1852486,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T23:52:47.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":3.97,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-23-000062","document":"wf-form4_168695955711451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000062/wf-form4_168695955711451.xml","form_type":"4"}},{"id":1852485,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":38749,"kind":"person","name":"Pande Vijay Satyanand","position":1,"cik":"0001840663","reported_name":"Pande Vijay Satyanand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T23:52:19.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":3.97,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-23-000060","document":"wf-form4_168695952896084.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000060/wf-form4_168695952896084.xml","form_type":"4"}},{"id":1852484,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T23:52:04.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":3.97,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-23-000059","document":"wf-form4_168695951498248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000059/wf-form4_168695951498248.xml","form_type":"4"}},{"id":1852483,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36353,"kind":"person","name":"NAZEM FARZAD","position":1,"cik":"0001234663","reported_name":"NAZEM FARZAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T23:51:51.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":3.97,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-23-000058","document":"wf-form4_168695949921353.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000058/wf-form4_168695949921353.xml","form_type":"4"}},{"id":1852482,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36352,"kind":"person","name":"Akinsanya Karen","position":1,"cik":"0001797672","reported_name":"Akinsanya Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T23:51:35.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":45000,"derivative":{"exercise_price":3.97,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001808805-23-000057","document":"wf-form4_168695948494043.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000057/wf-form4_168695948494043.xml","form_type":"4"}},{"id":1983913,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-01T22:20:05.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023."}],"balance_after":650000,"derivative":{"exercise_price":2,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001808805-23-000032","document":"wf-form4_167770917669467.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000032/wf-form4_167770917669467.xml","form_type":"4"}},{"id":1983912,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62838,"kind":"person","name":"Mowry Anna","position":1,"cik":"0001856938","reported_name":"Mowry Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-01T22:19:29.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023."}],"balance_after":160000,"derivative":{"exercise_price":2,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-23-000031","document":"wf-form4_167770915010174.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000031/wf-form4_167770915010174.xml","form_type":"4"}},{"id":1983910,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":87261,"kind":"person","name":"Godwin Mary E.","position":1,"cik":"0001439716","reported_name":"Godwin Mary E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-01T22:18:33.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023."}],"balance_after":160000,"derivative":{"exercise_price":2,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-23-000029","document":"wf-form4_167770909041820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000029/wf-form4_167770909041820.xml","form_type":"4"}},{"id":1983911,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62837,"kind":"person","name":"Mallick Parag","position":1,"cik":"0001857948","reported_name":"Mallick Parag","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Scientist"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-01T22:18:06.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023."}],"balance_after":280000,"derivative":{"exercise_price":2,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001808805-23-000028","document":"wf-form4_167770906065515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000028/wf-form4_167770906065515.xml","form_type":"4"}},{"id":1983909,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62834,"kind":"person","name":"Weld Gwen E","position":1,"cik":"0001378831","reported_name":"Weld Gwen E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-01T22:17:37.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023."}],"balance_after":160000,"derivative":{"exercise_price":2,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-23-000027","document":"wf-form4_167770904055529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000027/wf-form4_167770904055529.xml","form_type":"4"}},{"id":1983908,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":82464,"kind":"person","name":"Nelson Nicholas A.","position":1,"cik":"0001857944","reported_name":"Nelson Nicholas A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO & Senior VP, Bus. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-01T22:17:15.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023."}],"balance_after":160000,"derivative":{"exercise_price":2,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-23-000026","document":"wf-form4_167770900634743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000026/wf-form4_167770900634743.xml","form_type":"4"}},{"id":1983907,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62835,"kind":"person","name":"Sankar Subramanian","position":1,"cik":"0001856744","reported_name":"Sankar Subramanian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Product Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-01T22:16:38.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023."}],"balance_after":160000,"derivative":{"exercise_price":2,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-23-000025","document":"wf-form4_167770896995980.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000025/wf-form4_167770896995980.xml","form_type":"4"}},{"id":1983997,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62851,"kind":"person","name":"Murphy Matthew B.","position":1,"cik":"0001865778","reported_name":"Murphy Matthew B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-01T17:19:01.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023."}],"balance_after":160000,"derivative":{"exercise_price":2,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001808805-23-000030","document":"wf-form4_167770912315422.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865778/000180880523000030/wf-form4_167770912315422.xml","form_type":"4"}},{"id":2149979,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62835,"kind":"person","name":"Sankar Subramanian","position":1,"cik":"0001856744","reported_name":"Sankar Subramanian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Product Development"}}],"security":"Common Stock","published_at":"2022-09-28T20:01:57.000Z","date":"2022-09-27","kind":"purchase","acquired":true,"shares":5000,"price":2.0298,"value":10149.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 5,000 shares purchased in the price range of $2.02 to $2.04 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":91250,"source":{"system":"sec-edgar","filing":"0001808805-22-000101","document":"wf-form4_166439528878324.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000101/wf-form4_166439528878324.xml","form_type":"4"}},{"id":2149978,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62835,"kind":"person","name":"Sankar Subramanian","position":1,"cik":"0001856744","reported_name":"Sankar Subramanian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Product Development"}}],"security":"Common Stock","published_at":"2022-09-28T20:01:57.000Z","date":"2022-09-26","kind":"purchase","acquired":true,"shares":10000,"price":2.025,"value":20250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 10,000 shares purchased in the price range of $2.00 to $2.05 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,250 shares of Common Stock acquired on June 1, 2022 through the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":86250,"source":{"system":"sec-edgar","filing":"0001808805-22-000101","document":"wf-form4_166439528878324.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000101/wf-form4_166439528878324.xml","form_type":"4"}},{"id":2151304,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62834,"kind":"person","name":"Weld Gwen E","position":1,"cik":"0001378831","reported_name":"Weld Gwen E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Common Stock","published_at":"2022-09-27T01:26:42.000Z","date":"2022-09-23","kind":"purchase","acquired":true,"shares":30000,"price":2.0255,"value":60765.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 30,000 shares purchased in the price range of $1.97 to $2.0257 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001808805-22-000099","document":"wf-form4_166424198494990.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000099/wf-form4_166424198494990.xml","form_type":"4"}},{"id":2155866,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62835,"kind":"person","name":"Sankar Subramanian","position":1,"cik":"0001856744","reported_name":"Sankar Subramanian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Product Development"}}],"security":"Common Stock","published_at":"2022-09-19T21:50:15.000Z","date":"2022-09-16","kind":"purchase","acquired":true,"shares":35000,"price":2.1556,"value":75446.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 35,000 shares purchased in the price range of $2.10 to $2.21 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001808805-22-000097","document":"wf-form4_166362419701017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000097/wf-form4_166362419701017.xml","form_type":"4"}},{"id":2155865,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62835,"kind":"person","name":"Sankar Subramanian","position":1,"cik":"0001856744","reported_name":"Sankar Subramanian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Product Development"}}],"security":"Common Stock","published_at":"2022-09-19T21:50:15.000Z","date":"2022-09-15","kind":"purchase","acquired":true,"shares":40000,"price":2.1938,"value":87752.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 40,000 shares purchased in the price range of $2.145 to $2.2292 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001808805-22-000097","document":"wf-form4_166362419701017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000097/wf-form4_166362419701017.xml","form_type":"4"}},{"id":2177065,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62838,"kind":"person","name":"Mowry Anna","position":1,"cik":"0001856938","reported_name":"Mowry Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2022-08-22T23:40:43.000Z","date":"2022-08-19","kind":"purchase","acquired":true,"shares":17500,"price":2.2982,"value":40218.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 17,500 shares purchased in the price range of $2.29 to $2.30 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":56750,"source":{"system":"sec-edgar","filing":"0001808805-22-000095","document":"wf-form4_166121152658656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000095/wf-form4_166121152658656.xml","form_type":"4"}},{"id":2184449,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62851,"kind":"person","name":"Murphy Matthew B.","position":1,"cik":"0001865778","reported_name":"Murphy Matthew B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-08-16T20:19:19.000Z","date":"2022-08-15","kind":"purchase","acquired":true,"shares":7500,"price":2.841,"value":21307.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by the Murphy Family Trust. The reporting person is the Trustee of the Murphy Family Trust."}],"balance_after":54140,"source":{"system":"sec-edgar","filing":"0001808805-22-000093","document":"wf-form4_166069554291105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865778/000180880522000093/wf-form4_166069554291105.xml","form_type":"4"}},{"id":2184448,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62851,"kind":"person","name":"Murphy Matthew B.","position":1,"cik":"0001865778","reported_name":"Murphy Matthew B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-08-16T20:19:19.000Z","date":"2022-08-12","kind":"purchase","acquired":true,"shares":2500,"price":2.85,"value":7125.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by the Murphy Family Trust. The reporting person is the Trustee of the Murphy Family Trust."}],"balance_after":46640,"source":{"system":"sec-edgar","filing":"0001808805-22-000093","document":"wf-form4_166069554291105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865778/000180880522000093/wf-form4_166069554291105.xml","form_type":"4"}},{"id":2192022,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Common Stock","published_at":"2022-08-08T23:48:58.000Z","date":"2022-08-08","kind":"purchase","acquired":true,"shares":8346,"price":2.9288,"value":24443.7648,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 8,346 shares purchased in the price range of $2.90 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10014488,"source":{"system":"sec-edgar","filing":"0001808805-22-000089","document":"wf-form4_166000250690193.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000089/wf-form4_166000250690193.xml","form_type":"4"}},{"id":2192021,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62836,"kind":"person","name":"Patel Sujal M","position":1,"cik":"0001378830","reported_name":"Patel Sujal M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, President, and Secretary"}}],"security":"Common Stock","published_at":"2022-08-08T23:48:58.000Z","date":"2022-08-05","kind":"purchase","acquired":true,"shares":41654,"price":2.9204,"value":121646.3416,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average share price of an aggregate total of 41,654 shares purchased in the price range of $2.76 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":10006142,"source":{"system":"sec-edgar","filing":"0001808805-22-000089","document":"wf-form4_166000250690193.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000089/wf-form4_166000250690193.xml","form_type":"4"}},{"id":2195950,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":87261,"kind":"person","name":"Godwin Mary E.","position":1,"cik":"0001439716","reported_name":"Godwin Mary E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP, Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-04T01:15:02.000Z","date":"2022-08-03","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is July 1, 2022."}],"balance_after":30000,"derivative":{"exercise_price":2.83,"expiration_date":"2032-08-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001808805-22-000087","document":"wf-form4_165957568676746.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000087/wf-form4_165957568676746.xml","form_type":"4"}},{"id":2220245,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":62838,"kind":"person","name":"Mowry Anna","position":1,"cik":"0001856938","reported_name":"Mowry Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2022-06-28T22:17:38.000Z","date":"2022-06-27","kind":"purchase","acquired":true,"shares":5500,"price":2.7499,"value":15124.45,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,250 shares of Common Stock acquired on June 1, 2022 through the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":39250,"source":{"system":"sec-edgar","filing":"0001808805-22-000075","document":"wf-form4_165645463634483.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000075/wf-form4_165645463634483.xml","form_type":"4"}},{"id":2228084,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T21:43:59.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":86467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each vesting date, the shares subject to the Option shall vest on a monthly basis for twelve consecutive months, on the same day of the month as the Grant Date.  The Grant Date was June 15, 2022."}],"balance_after":86467,"derivative":{"exercise_price":2.7,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":86467},"source":{"system":"sec-edgar","filing":"0001062993-22-015188","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000106299322015188/form4.xml","form_type":"4"}},{"id":2228378,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":2,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T21:43:40.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":86467,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to Michael Altman's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each vesting date, the shares subject to the Option shall vest on a monthly basis for twelve consecutive months, on the same day of the month as the Grant Date.  The Grant Date was June 15, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of options to purchase shares of the Issuer's common stock awarded to Michael Altman in connection with his role as a member of the Issuer's Board of Directors.  Mr. Altman is affiliated with the Advisor.  The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Altman's board service through a partial management fee offset."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of the securities reported on this form, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":86467,"derivative":{"exercise_price":2.7,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":86467},"source":{"system":"sec-edgar","filing":"0001062993-22-015186","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299322015186/form4.xml","form_type":"4"}},{"id":2230113,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36353,"kind":"person","name":"NAZEM FARZAD","position":1,"cik":"0001234663","reported_name":"NAZEM FARZAD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T00:05:11.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":86467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":86467,"derivative":{"exercise_price":2.7,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":86467},"source":{"system":"sec-edgar","filing":"0001808805-22-000073","document":"wf-form4_165542429207145.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000073/wf-form4_165542429207145.xml","form_type":"4"}},{"id":2230112,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36351,"kind":"person","name":"McIlwain Matthew S","position":1,"cik":"0001381752","reported_name":"McIlwain Matthew S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T00:04:48.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":86467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":86467,"derivative":{"exercise_price":2.7,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":86467},"source":{"system":"sec-edgar","filing":"0001808805-22-000072","document":"wf-form4_165542426104251.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000072/wf-form4_165542426104251.xml","form_type":"4"}},{"id":2230111,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T00:04:15.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":86467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":86467,"derivative":{"exercise_price":2.7,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":86467},"source":{"system":"sec-edgar","filing":"0001808805-22-000071","document":"wf-form4_165542423007735.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000071/wf-form4_165542423007735.xml","form_type":"4"}},{"id":2230109,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T00:03:42.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":86467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":86467,"derivative":{"exercise_price":2.7,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":86467},"source":{"system":"sec-edgar","filing":"0001808805-22-000070","document":"wf-form4_165542420534044.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000070/wf-form4_165542420534044.xml","form_type":"4"}},{"id":2230110,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":36352,"kind":"person","name":"Akinsanya Karen","position":1,"cik":"0001797672","reported_name":"Akinsanya Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T00:03:22.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":14411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month)."}],"balance_after":14411,"derivative":{"exercise_price":2.7,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":14411},"source":{"system":"sec-edgar","filing":"0001808805-22-000069","document":"wf-form4_165542418669211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000069/wf-form4_165542418669211.xml","form_type":"4"}}],"next_cursor":"2022-06-17T00:03:22.000000Z,2230110"}